CClinicalTrials.gg
CompletedNCT06326762Updated Mar 22, 2024

Gap CO2 in Septic Patient to Predict Cardiomyopathy Septic

An observational study in Gap co2, Cardiac Output, Low and Cardiac Defect, sponsored by Mohammed VI University Hospital. Completed at 1 site in Morocco. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-03-22.

Sponsored by Mohammed VI University Hospital · Observational

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
98
Ages
18 Years and older
Sex
All
01

Study summary

the investigators included 98 patients admitted for sepsis and septic shock (68.4% men, 31.6% women) with an average age of 60.42 years ± 15.13, ranging from 21 to 96 years. The average length of hospital stay was 7.53 days. The most noted medical histories were diabetes (38.8%), hypertension (28.6%), and renal insufficiency (17.1%). Regarding laboratory findings: the mean white blood cell count was 15,985.16 cells/mm³, the mean C-reactive protein (CRP) level was 227.69 mg/L, and the mean procalcitonin level was 50.43 µg/L. In terms of blood gas analysis: the mean lactate level was 3.67 mmol/L, and the mean PCO2 gap (DELTAPCO2) was 4.85. All our patients were continuously monitored by pulse wave analysis: the mean cardiac output was 5.69 L/min, and the mean cardiac index was 4.14 L/s/m² All our patients underwent an echocardiogram, which is a routine examination in our department and is performed at the patient's bedside. The average left ventricular ejection fraction (LVEF) was 51.73%, and the average subaortic peak velocity (ITV) was 14.66 cm.

Subsequently. the investigators examined the clinical and paraclinical profile of patients with septic cardiomyopathy. the investigators identified 19 patients with this condition, while 79 patients did not exhibit cardiac involvement. The percentage was significantly higher in the population with cardiac involvement, accounting for 28.3%. Among the patients with cardiac involvement, 76.5% had a PCO2 gap (DELTAPCO2) ≥ 6 mmHg, a significantly reduced cardiac output with an average of 3.3 L/min, and a predominantly low cardiac index, with 64.3% having an index \< 2.2 L/min/m². The mortality rate was significantly increased at 73.7%.

02

Conditions studied

  • Gap co2
  • Cardiac Output, Low
  • Cardiac Defect

Keywords

  • cardiac
  • CO2
  • septic
03

In context

Cardiomyopathies

1,176 studies on the registry are indexed under Cardiomyopathies; 287 are open to participants now.

This study's enrollment of 98 is below the median of 153 across 515 observational studies indexed under Cardiomyopathies.

Browse Cardiomyopathies studies →

Lead sponsor

Mohammed VI University Hospital is the lead sponsor of 11 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

We included patients diagnosed with sepsis/septic shock admitted at various points in time to the intensive care units of the Mohammed VI University Hospital in Oujda.

Inclusion criteria

  • Patients admitted to the intensive care unit
  • sepsis or septic shock
  • at least one echocardiogram and were monitored by pulse wave contour analysis
  • stay of 72 hours in the intensive care unit

Exclusion criteria

Exclusion Criteria:

  • Patients without sepsis or septic shock.
  • Patients with COVID-19.
  • Patients who died within 48 hours of hospitalization.
  • Cases with incomplete medical records or patients not monitored.
  • Patient with pre-existing cardiac conditions.
  • post-operative patients from cardiac and thoracic surgeries.
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
98 participants (actual)
Patient registry
No

Groups and cohorts

  • Myocardial Dysfunction

    Other: comparaison

  • No Myocardial Dysfunction

    Other: comparaison

Interventions

  • Othercomparaison

    description indicate

06

What researchers measure

Primary outcomes

  1. gapCO2

    significative in cardiomyopathy septic

    Time frame: 10 mounths

07

Study locations

1 site
  • younes Oujidi
    Berkane, 9999, Morocco
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 22, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06326762
Lead sponsor
Mohammed VI University Hospital
Responsible party
Younes Oujidi (doctor, Mohammed VI University Hospital) — Principal investigator
First posted
Mar 22, 2024
Start date
Jan 1, 2023
Primary completion
Oct 30, 2023
Completion
Oct 30, 2023
Last update
Mar 22, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion